Pharmaceuticals & Biotechnology

TuHURA Biosciences, Inc./NV CFO pay

Dan Dearborn, Chief Financial Officer. Fiscal year 2025, as reported to the SEC.

Total compensation

$1.8M

$1,832,036 for fiscal 2025: the Summary Compensation Table total, with stock and option awards at their grant-date value.

Definitive proxy statement, filed 2026-07-09SEC accession number 0001193125-26-299680

In context

The median CFO among 229 Pharmaceuticals & Biotechnology companies with under $100M in revenue was paid $1.1M. The middle half ranged from $497K to $2M.

Dan Dearborn's total is above that median.

See how your pay compares to TuHURA Biosciences, Inc./NV's peers

CFOCompensation breaks this total into salary, bonus, stock and option awards, builds a peer set of comparable companies around it, and places your own package against them, with every figure cited to its filing.

Join the Waitlist

Source: TuHURA Biosciences, Inc./NV's definitive proxy statement (SEC Form DEF 14A), Summary Compensation Table, fiscal year 2025. Figures are as reported by the company and are not adjusted or estimated. Context figures are from CFOCompensation's snapshot of SEC filings as of 2026-11-02. Private-company pay is not covered, and smaller reporting companies may omit the CFO under Item 402(m). Not financial, legal or compensation-consulting advice.

See an error on this page? Email eddy@cfocompensation.com with the filing and we will correct it.